1. The efficacy of measurement of the serum beta-d glucan in the patients with biliary atresia
- Author
-
Koichi Mizuta, Yoshiyuki Ihara, Taizen Urahashi, Noriki Okada, Hideo Kawarasaki, Yoshikazu Yasuda, Yukihiro Sanada, Taiichi Wakiya, and Naoya Yamada
- Subjects
Male ,medicine.medical_specialty ,beta-Glucans ,Adolescent ,medicine.medical_treatment ,Liver transplantation ,Gastroenterology ,End Stage Liver Disease ,Liver disease ,Biliary Atresia ,Biliary atresia ,Internal medicine ,Humans ,Medicine ,Child ,Vein ,Retrospective Studies ,Portal Vein ,business.industry ,Infant ,Reproducibility of Results ,General Medicine ,Mononuclear phagocyte system ,Prognosis ,medicine.disease ,Liver Transplantation ,Peripheral ,medicine.anatomical_structure ,Liver ,Child, Preschool ,Preoperative Period ,Pediatrics, Perinatology and Child Health ,Disease Progression ,Beta d glucan ,Female ,Surgery ,Liver function ,business ,Biomarkers ,Follow-Up Studies - Abstract
The pediatric end-stage liver disease (PELD) score is not a direct index that reflects the degree of hepatocellular injury. Beta-d glucan (BDG) in the portal vein blood is processed by the hepatic reticuloendothelial system. It is possible that the hepatic clearance of BDG may be used as a biological index to assess the liver function. In this study, the relationship between PELD score and hepatic clearance of BDG was made clear in order to study the efficacy of measurement of the serum BDG. This study including 21 patients with biliary atresia (BA) who underwent liver transplantation (LT) was performed. The BDG was measured in the preoperative peripheral vein blood and the portal vein blood at the time of LT. The portal vein blood showed a significantly high level of BDG than the peripheral vein blood (p
- Published
- 2012